Laidlaw downgraded Evoke Pharma (EVOK) to Hold from Buy after QOL Medical announced a deal to acquire Evoke for $11.00 per share in cash at closing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVOK: